Key Components of Inflammasome and Pyroptosis Pathways Are Deficient in Canines and Felines, Possibly Affecting Their Response to SARS-CoV-2 Infection.

Szczegóły
Abstrakt

Tytuł:: Key Components of Inflammasome and Pyroptosis Pathways Are Deficient in Canines and Felines, Possibly Affecting Their Response to SARS-CoV-2 Infection.
Autorzy:: Cui H; Institute of Basic Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.; Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Zhang L; Institute of Basic Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.; Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Źródło:: Frontiers in immunology [Front Immunol] 2021 Jan 28; Vol. 11, pp. 592622. Date of Electronic Publication: 2021 Jan 28 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:: Cat Diseases*/immunology
Cat Diseases*/virology
Dog Diseases*/immunology
Dog Diseases*/virology
COVID-19/*immunology
COVID-19/*veterinary
Inflammasomes/*immunology
Pyroptosis/*immunology
Animals ; Cats ; Cytokine Release Syndrome/genetics ; Cytokine Release Syndrome/immunology ; Dogs ; Genomics ; Humans ; Inflammasomes/genetics ; Pyroptosis/genetics ; SARS-CoV-2 ; Tigers
References:: Biochem Biophys Res Commun. 2020 May 21;526(1):165-169. (PMID: 32201080)
Nat Rev Immunol. 2020 Mar;20(3):143-157. (PMID: 31690840)
Sci Rep. 2016 Feb 24;6:21722. (PMID: 26906452)
Virology. 2015 Nov;485:330-9. (PMID: 26331680)
J Med Virol. 2020 Sep;92(9):1649-1656. (PMID: 32239522)
BMC Bioinformatics. 2015 Oct 06;16:322. (PMID: 26445311)
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):710-713. (PMID: 32525853)
Apoptosis. 2020 Aug;25(7-8):474-480. (PMID: 32533513)
Curr Biol. 2020 Apr 6;30(7):1346-1351.e2. (PMID: 32197085)
J Exp Med. 2012 Oct 22;209(11):1969-83. (PMID: 23045604)
BMC Evol Biol. 2012 Aug 07;12:140. (PMID: 22871040)
Science. 2020 May 29;368(6494):1016-1020. (PMID: 32269068)
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. (PMID: 29788355)
Nat Commun. 2017 Jan 03;8:14128. (PMID: 28045099)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549. (PMID: 29722887)
Nature. 2017 Jul 6;547(7661):99-103. (PMID: 28459430)
Clin Chim Acta. 2020 Oct;509:280-287. (PMID: 32531256)
Front Immunol. 2020 May 08;11:939. (PMID: 32574256)
Nucleic Acids Res. 2020 Jan 8;48(D1):D265-D268. (PMID: 31777944)
J Comput Chem. 2004 Oct;25(13):1605-12. (PMID: 15264254)
Nature. 2020 Oct;586(7831):776-778. (PMID: 32408337)
J Cell Biol. 2016 Jun 20;213(6):617-29. (PMID: 27325789)
Front Microbiol. 2019 Jan 29;10:50. (PMID: 30761102)
J Exp Med. 2021 Mar 1;218(3):. (PMID: 33231615)
Science. 2020 May 29;368(6494):. (PMID: 32299851)
Microbiol Resour Announc. 2020 May 28;9(22):. (PMID: 32467283)
Nat Microbiol. 2019 May;4(5):789-799. (PMID: 30804542)
Cell Host Microbe. 2018 Mar 14;23(3):297-301.e4. (PMID: 29478775)
Transbound Emerg Dis. 2020 Aug 5;:. (PMID: 32757470)
Front Immunol. 2020 Jun 26;11:1580. (PMID: 32670297)
PLoS Pathog. 2020 May 14;16(5):e1008421. (PMID: 32407364)
Biochem Biophys Res Commun. 2009 Jun 26;384(2):226-30. (PMID: 19394309)
J Immunol. 2020 Jul 15;205(2):307-312. (PMID: 32493814)
J Hepatol. 2020 Nov;73(5):1258-1262. (PMID: 32645361)
J Biol Chem. 2020 Oct 9;295(41):14040-14052. (PMID: 32763970)
Int Immunol. 2018 Apr 25;30(5):183-193. (PMID: 29617808)
Transbound Emerg Dis. 2020 Nov;67(6):2324-2328. (PMID: 32500944)
Nature. 2020 Mar;579(7799):415-420. (PMID: 32188940)
Nature. 2016 Jul 7;535(7610):111-6. (PMID: 27281216)
Front Immunol. 2020 Jun 23;11:1518. (PMID: 32655582)
FASEB J. 2019 Aug;33(8):8865-8877. (PMID: 31034780)
Cell Death Discov. 2019 Jun 5;5:101. (PMID: 31231549)
Annu Rev Virol. 2018 Sep 29;5(1):341-362. (PMID: 30265633)
Science. 2013 Jul 12;341(6142):172-5. (PMID: 23765277)
Contributed Indexing:: Keywords: Severe Acute Respiratory Syndrome Corona Virus 2; canines; felines; inflammasome; pyroptosis
Substance Nomenclature:: 0 (Inflammasomes)
Entry Date(s):: Date Created: 20210215 Date Completed: 20210218 Latest Revision: 20210218
Update Code:: 20240104
PubMed Central ID:: PMC7876337
DOI:: 10.3389/fimmu.2020.592622
PMID:: 33584656
: Czasopismo naukowe

Full Text Finder

SARS-CoV-2 causes the ongoing COVID-19 pandemic. Natural SARS-COV-2 infection has been detected in dogs, cats and tigers. However, the symptoms in canines and felines were mild. The underlying mechanisms are unknown. Excessive activation of inflammasome pathways can trigger cytokine storm and severe damage to host. In current study, we performed a comparative genomics study of key components of inflammasome and pyroptosis pathways in dogs, cats and tigers. Cats and tigers do not have AIM2 and NLRP1. Dogs do not contain AIM2, and encode a short form of NLRC4. The activation sites in GSDMB were absent in dogs, cats and tigers, while GSDME activation sites in cats and tigers were abolished. We propose that deficiencies of inflammasome and pyroptosis pathways might provide an evolutionary advantage against SARS-CoV-2 by reducing cytokine storm-induced host damage. Our findings will shed important lights on the mild symptoms in canines and felines infected with SARS-CoV-2.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Cui and Zhang.)

Informacja